Senores Pharmaceuticals Ltd
Q1 FY27, unaudited
- Revenue
- ₹180.21 Cr
- Profit after tax
- ₹30.45 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | 6M FY26 |
|---|---|---|---|
| Revenue from operations | 180.21 | +30.60% | 175.19 |
| Other income | 2.81 | −16.37% | 17.67 |
| Total income | 183.02 | +29.48% | 192.86 |
| Employee benefit expense | 29.91 | +38.15% | 30.32 |
| Finance costs | 7.17 | +42.26% | 8.46 |
| Depreciation & amortisation | 9.94 | +65.67% | 9.30 |
| Total expenses | 143.56 | +24.99% | 145.46 |
| Profit before tax | 39.46 | +48.96% | 47.40 |
| Tax expense | 9.01 | +69.68% | 10.73 |
| Profit after tax | 30.45 | +43.77% | 36.67 |
| Total comprehensive income | 30.96 | +43.00% | 78.59 |
| Earnings per share, basic | ₹6.61 | ₹7.96 |
|---|---|---|
| Earnings per share, diluted | ₹6.60 | ₹7.96 |
Earnings call
Q1 FY27Senores Pharmaceuticals reported consolidated revenue of Rs 180 crore for Q1 FY27, up 36% year-over-year, with EBITDA of Rs 54 crore growing 87% and PAT of Rs 31 crore growing 56%. Regulated market revenue grew 42% while emerging market revenue grew 30%, and management said the ANDA portfolio nearly doubled to 58 approved ANDAs as of June 2026 from 30 a year earlier. Management reiterated full-year FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth, and outlined a three-to-four-year revenue target of Rs 2,500 crore to Rs 3,000 crore.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 67 published by the exchange
08 Oct 2026
28 Sept 2026
25 Sept 2026
24 Sept 2026
Insider trading21 Sept 2026
21 Sept 2026
FilingClarification sought from Senores Pharmaceuticals Ltd
11 Sept 2026
09 Sept 2026
04 Sept 2026
Filing27 Aug 2026
27 Aug 2026
Filing26 Aug 2026
Filing
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 08 Oct 2026.